Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspective

BACKGROUND: Anthracycline-treated childhood cancer survivors are at higher risk of cardiotoxicity, especially with cumulative doses received above 250 mg/m(2). Dexrazoxane is the only option recommended for cardiotoxicity prevention in high-risk patients supported by randomised trials but its cost-e...

Descripción completa

Detalles Bibliográficos
Autores principales: Dewilde, Sarah, Carroll, Kevin, Nivelle, Emilia, Sawyer, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011276/
https://www.ncbi.nlm.nih.gov/pubmed/32063753
http://dx.doi.org/10.1186/s12962-020-0205-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011276/
https://www.ncbi.nlm.nih.gov/pubmed/32063753
http://dx.doi.org/10.1186/s12962-020-0205-4

Ejemplares similares